NanoViricides, Inc. (NYSE: NNVC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon [Yahoo! Finance]
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
NanoViricides, Inc. (NYSE: NNVC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
NanoViricides, Inc. (NYSE: NNVC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.